Biogen
-
Drugmaker Biogen to buy all outstanding shares of Sage Therapeutics
Jan 11, 2025Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter’s stock up 34% in extended... -
U.S. FDA approves Biogen’s SPINRAZA™, the first treatment for spinal muscular atrophy
Dec 24, 2016News Hour: The U.S. Food and Drug Administration (FDA) approved Biogen’s SPINRAZA™ (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved... -
Biogen reports second quarter 2016 revenues of $2.9 billion
Aug 9, 2016News Hour: Biogen Inc. (NASDAQ: BIIB) reported second quarter 2016 financial results, including: Total revenues of $2.9 billion, a 12% increase versus the same period in the prior year. Growth was driven by increases in worldwide... -
Once-monthly Zinbryta™ (Daclizumab) approved in European Union for treatment of Multiple Sclerosis
Aug 9, 2016News Hour: The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced last month.... -
Interim analysis of phase 3 endear study in infantile-onset spinal muscular atrophy
Aug 9, 2016News Hour: Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen...
